| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Autism Spectrum Disorder | 11 | 2022 | 164 | 3.390 |
Why?
|
| Pregnancy Complications, Infectious | 10 | 2024 | 142 | 3.200 |
Why?
|
| Influenza, Human | 10 | 2024 | 282 | 3.070 |
Why?
|
| Influenza Vaccines | 10 | 2024 | 290 | 2.600 |
Why?
|
| Vaccination | 19 | 2024 | 674 | 2.250 |
Why?
|
| Whooping Cough | 4 | 2022 | 75 | 2.060 |
Why?
|
| Autistic Disorder | 5 | 2017 | 105 | 1.800 |
Why?
|
| Pregnancy | 22 | 2024 | 1516 | 1.760 |
Why?
|
| Humans | 72 | 2024 | 18430 | 1.680 |
Why?
|
| Measles | 3 | 2022 | 26 | 1.640 |
Why?
|
| Measles-Mumps-Rubella Vaccine | 4 | 2022 | 67 | 1.590 |
Why?
|
| Female | 54 | 2024 | 13136 | 1.510 |
Why?
|
| Infant | 15 | 2024 | 1245 | 1.450 |
Why?
|
| Immunization Schedule | 5 | 2021 | 133 | 1.380 |
Why?
|
| Young Adult | 26 | 2024 | 2518 | 1.360 |
Why?
|
| Diphtheria-Tetanus-acellular Pertussis Vaccines | 3 | 2019 | 95 | 1.310 |
Why?
|
| Vaccines | 4 | 2024 | 222 | 1.290 |
Why?
|
| Child | 17 | 2024 | 2571 | 1.260 |
Why?
|
| Adult | 41 | 2024 | 7910 | 1.240 |
Why?
|
| Vaccination Coverage | 4 | 2021 | 45 | 1.240 |
Why?
|
| California | 20 | 2024 | 2365 | 1.220 |
Why?
|
| Hospitalization | 10 | 2024 | 847 | 1.160 |
Why?
|
| Male | 34 | 2024 | 10440 | 1.040 |
Why?
|
| Case-Control Studies | 17 | 2023 | 1173 | 0.980 |
Why?
|
| Child, Preschool | 12 | 2024 | 1478 | 0.940 |
Why?
|
| Adolescent | 22 | 2024 | 3798 | 0.930 |
Why?
|
| Mumps | 2 | 2020 | 12 | 0.900 |
Why?
|
| Mothers | 3 | 2023 | 110 | 0.860 |
Why?
|
| Prenatal Exposure Delayed Effects | 2 | 2015 | 159 | 0.820 |
Why?
|
| Immunologic Factors | 1 | 2022 | 27 | 0.810 |
Why?
|
| Pregnancy Outcome | 3 | 2024 | 159 | 0.800 |
Why?
|
| Prenatal Care | 2 | 2020 | 134 | 0.790 |
Why?
|
| Seizures, Febrile | 1 | 2022 | 47 | 0.790 |
Why?
|
| Fever | 3 | 2022 | 60 | 0.780 |
Why?
|
| Retrospective Studies | 18 | 2024 | 2550 | 0.770 |
Why?
|
| Vaccines, Combined | 7 | 2023 | 91 | 0.740 |
Why?
|
| Child Development Disorders, Pervasive | 3 | 2017 | 35 | 0.720 |
Why?
|
| Infant, Newborn | 8 | 2024 | 872 | 0.690 |
Why?
|
| Risk Factors | 11 | 2024 | 3449 | 0.660 |
Why?
|
| Insurance, Health | 2 | 2021 | 217 | 0.650 |
Why?
|
| Early Diagnosis | 2 | 2019 | 40 | 0.640 |
Why?
|
| Cytokines | 2 | 2019 | 30 | 0.640 |
Why?
|
| Breast Neoplasms | 6 | 2016 | 1037 | 0.630 |
Why?
|
| Antigens | 1 | 2018 | 7 | 0.620 |
Why?
|
| Infection | 1 | 2018 | 17 | 0.620 |
Why?
|
| Pregnancy Trimester, First | 1 | 2017 | 39 | 0.580 |
Why?
|
| Developmental Disabilities | 3 | 2019 | 53 | 0.560 |
Why?
|
| Chickenpox Vaccine | 4 | 2022 | 101 | 0.560 |
Why?
|
| Cohort Studies | 11 | 2023 | 2672 | 0.560 |
Why?
|
| Delivery of Health Care | 3 | 2022 | 444 | 0.530 |
Why?
|
| C-Reactive Protein | 1 | 2016 | 58 | 0.530 |
Why?
|
| Birth Intervals | 1 | 2015 | 10 | 0.520 |
Why?
|
| Incidence | 8 | 2024 | 1314 | 0.520 |
Why?
|
| Clinical Competence | 1 | 2015 | 108 | 0.500 |
Why?
|
| Hypersensitivity | 1 | 2015 | 21 | 0.500 |
Why?
|
| Databases, Factual | 1 | 2016 | 327 | 0.500 |
Why?
|
| Autoimmune Diseases | 1 | 2015 | 23 | 0.490 |
Why?
|
| Seasons | 3 | 2024 | 105 | 0.480 |
Why?
|
| Physicians | 1 | 2015 | 141 | 0.480 |
Why?
|
| Odds Ratio | 5 | 2023 | 701 | 0.460 |
Why?
|
| Middle Aged | 21 | 2024 | 8284 | 0.460 |
Why?
|
| Premature Birth | 5 | 2024 | 138 | 0.450 |
Why?
|
| United States | 14 | 2024 | 4164 | 0.410 |
Why?
|
| Immunocompromised Host | 2 | 2021 | 20 | 0.410 |
Why?
|
| Logistic Models | 5 | 2020 | 962 | 0.410 |
Why?
|
| Infant, Small for Gestational Age | 3 | 2024 | 59 | 0.400 |
Why?
|
| Risk Assessment | 6 | 2022 | 1143 | 0.390 |
Why?
|
| Asthma | 1 | 2015 | 390 | 0.390 |
Why?
|
| Fertilization | 1 | 2011 | 3 | 0.390 |
Why?
|
| Vaccines, Inactivated | 3 | 2020 | 70 | 0.390 |
Why?
|
| Vaccines, Attenuated | 2 | 2022 | 47 | 0.380 |
Why?
|
| Aged | 15 | 2024 | 6417 | 0.380 |
Why?
|
| Surveys and Questionnaires | 1 | 2015 | 1389 | 0.380 |
Why?
|
| Risk | 5 | 2016 | 552 | 0.370 |
Why?
|
| Follow-Up Studies | 4 | 2020 | 1269 | 0.320 |
Why?
|
| Central Nervous System Stimulants | 2 | 2011 | 29 | 0.320 |
Why?
|
| Pregnant Women | 2 | 2021 | 44 | 0.320 |
Why?
|
| RNA, Messenger | 6 | 2023 | 80 | 0.310 |
Why?
|
| Proportional Hazards Models | 4 | 2020 | 743 | 0.270 |
Why?
|
| Breast Density | 1 | 2016 | 31 | 0.270 |
Why?
|
| Aged, 80 and over | 8 | 2022 | 2003 | 0.260 |
Why?
|
| Ambulatory Care | 3 | 2022 | 266 | 0.260 |
Why?
|
| Time Factors | 4 | 2022 | 1136 | 0.250 |
Why?
|
| Insulin, Long-Acting | 1 | 2013 | 12 | 0.230 |
Why?
|
| Patient Acceptance of Health Care | 3 | 2024 | 407 | 0.220 |
Why?
|
| Cluster Analysis | 1 | 2023 | 96 | 0.220 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 2 | 2011 | 70 | 0.220 |
Why?
|
| Mucocutaneous Lymph Node Syndrome | 1 | 2022 | 19 | 0.210 |
Why?
|
| Rotavirus Vaccines | 1 | 2022 | 50 | 0.210 |
Why?
|
| Pneumococcal Infections | 1 | 2022 | 53 | 0.210 |
Why?
|
| Herpesvirus 3, Human | 1 | 2012 | 49 | 0.210 |
Why?
|
| Pericarditis | 1 | 2022 | 14 | 0.210 |
Why?
|
| Cataplexy | 1 | 2022 | 5 | 0.210 |
Why?
|
| Narcolepsy | 1 | 2022 | 6 | 0.210 |
Why?
|
| Myocarditis | 1 | 2022 | 18 | 0.210 |
Why?
|
| Emergency Service, Hospital | 5 | 2023 | 382 | 0.200 |
Why?
|
| Bell Palsy | 1 | 2022 | 17 | 0.200 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2013 | 124 | 0.200 |
Why?
|
| Thrombocytopenia | 1 | 2022 | 15 | 0.200 |
Why?
|
| Measles Vaccine | 1 | 2022 | 21 | 0.200 |
Why?
|
| Pneumococcal Vaccines | 1 | 2022 | 80 | 0.200 |
Why?
|
| Vaccines, Synthetic | 4 | 2022 | 43 | 0.200 |
Why?
|
| Infant, Premature | 1 | 2022 | 60 | 0.190 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2022 | 116 | 0.190 |
Why?
|
| Herpes Zoster | 1 | 2012 | 88 | 0.190 |
Why?
|
| Rubella | 1 | 2020 | 6 | 0.190 |
Why?
|
| Spatial Analysis | 1 | 2020 | 12 | 0.190 |
Why?
|
| Prostatic Neoplasms | 1 | 2013 | 298 | 0.190 |
Why?
|
| Geography | 1 | 2020 | 41 | 0.190 |
Why?
|
| Bursitis | 1 | 2020 | 4 | 0.180 |
Why?
|
| Shoulder Joint | 1 | 2020 | 5 | 0.180 |
Why?
|
| Telemedicine | 1 | 2024 | 184 | 0.180 |
Why?
|
| Pandemics | 4 | 2024 | 292 | 0.180 |
Why?
|
| Neoplasms, Second Primary | 1 | 2010 | 31 | 0.180 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 1 | 2010 | 43 | 0.180 |
Why?
|
| Pregnancy Trimester, Second | 2 | 2019 | 26 | 0.180 |
Why?
|
| Eggs | 1 | 2020 | 9 | 0.180 |
Why?
|
| Influenza A virus | 1 | 2020 | 14 | 0.180 |
Why?
|
| Disease Outbreaks | 1 | 2020 | 39 | 0.180 |
Why?
|
| Communicable Diseases | 1 | 2020 | 15 | 0.180 |
Why?
|
| Carcinoma in Situ | 1 | 2009 | 17 | 0.170 |
Why?
|
| Comorbidity | 3 | 2019 | 619 | 0.170 |
Why?
|
| Child Development | 1 | 2020 | 52 | 0.170 |
Why?
|
| Chemokines | 1 | 2019 | 8 | 0.170 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2009 | 57 | 0.170 |
Why?
|
| Croup | 1 | 2018 | 4 | 0.160 |
Why?
|
| Residence Characteristics | 1 | 2020 | 256 | 0.160 |
Why?
|
| Otitis Media | 1 | 2018 | 21 | 0.150 |
Why?
|
| Hispanic Americans | 1 | 2020 | 428 | 0.150 |
Why?
|
| Gastrointestinal Diseases | 1 | 2018 | 28 | 0.150 |
Why?
|
| Body Constitution | 1 | 2007 | 39 | 0.150 |
Why?
|
| Respiratory Tract Infections | 1 | 2018 | 54 | 0.150 |
Why?
|
| Neoplasms | 1 | 2012 | 457 | 0.150 |
Why?
|
| Breast Diseases | 1 | 2007 | 17 | 0.150 |
Why?
|
| African Americans | 1 | 2020 | 490 | 0.150 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2009 | 249 | 0.150 |
Why?
|
| Infant, Low Birth Weight | 1 | 2017 | 37 | 0.150 |
Why?
|
| Prevalence | 2 | 2022 | 911 | 0.140 |
Why?
|
| Colorectal Neoplasms | 1 | 2013 | 656 | 0.140 |
Why?
|
| Proof of Concept Study | 1 | 2016 | 3 | 0.140 |
Why?
|
| Pregnancy Complications | 1 | 2019 | 193 | 0.140 |
Why?
|
| Gestational Age | 1 | 2017 | 119 | 0.140 |
Why?
|
| Pesticides | 1 | 2016 | 7 | 0.140 |
Why?
|
| Hydrocarbons, Chlorinated | 1 | 2016 | 5 | 0.140 |
Why?
|
| Pertussis Vaccine | 1 | 2016 | 17 | 0.140 |
Why?
|
| Diphtheria | 1 | 2016 | 14 | 0.140 |
Why?
|
| Polychlorinated Biphenyls | 1 | 2016 | 11 | 0.140 |
Why?
|
| Tetanus | 1 | 2016 | 18 | 0.140 |
Why?
|
| Intellectual Disability | 1 | 2016 | 27 | 0.140 |
Why?
|
| Women's Health | 1 | 2007 | 207 | 0.140 |
Why?
|
| Gene Expression Profiling | 1 | 2006 | 34 | 0.140 |
Why?
|
| Mammography | 3 | 2016 | 174 | 0.140 |
Why?
|
| Selective Estrogen Receptor Modulators | 1 | 2006 | 12 | 0.130 |
Why?
|
| Drug Utilization Review | 1 | 2006 | 26 | 0.130 |
Why?
|
| Prospective Studies | 2 | 2020 | 1314 | 0.130 |
Why?
|
| Raloxifene Hydrochloride | 1 | 2006 | 13 | 0.130 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2006 | 55 | 0.130 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2013 | 760 | 0.130 |
Why?
|
| Maternal Exposure | 1 | 2016 | 60 | 0.130 |
Why?
|
| Environmental Pollutants | 1 | 2016 | 45 | 0.130 |
Why?
|
| Cardiovascular Diseases | 1 | 2011 | 630 | 0.130 |
Why?
|
| Postpartum Period | 1 | 2016 | 93 | 0.130 |
Why?
|
| State Health Plans | 1 | 2005 | 44 | 0.120 |
Why?
|
| Age Distribution | 3 | 2012 | 261 | 0.120 |
Why?
|
| Prognosis | 3 | 2020 | 624 | 0.110 |
Why?
|
| Antipyretics | 1 | 2013 | 4 | 0.110 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2006 | 350 | 0.110 |
Why?
|
| Genome-Wide Association Study | 1 | 2013 | 252 | 0.100 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2013 | 412 | 0.100 |
Why?
|
| Immunization, Secondary | 2 | 2022 | 64 | 0.100 |
Why?
|
| Laboratories | 2 | 2021 | 23 | 0.100 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2013 | 414 | 0.100 |
Why?
|
| European Continental Ancestry Group | 2 | 2016 | 554 | 0.090 |
Why?
|
| Multivariate Analysis | 1 | 2011 | 598 | 0.090 |
Why?
|
| Early Detection of Cancer | 2 | 2016 | 526 | 0.080 |
Why?
|
| Tamoxifen | 2 | 2009 | 60 | 0.070 |
Why?
|
| Antineoplastic Agents, Hormonal | 2 | 2009 | 65 | 0.070 |
Why?
|
| SEER Program | 1 | 2016 | 101 | 0.070 |
Why?
|
| Delivery of Health Care, Integrated | 2 | 2021 | 567 | 0.060 |
Why?
|
| Insulin Glargine | 1 | 2013 | 9 | 0.060 |
Why?
|
| Hematologic Neoplasms | 1 | 2012 | 8 | 0.050 |
Why?
|
| RNA, Messenger, Stored | 1 | 2022 | 4 | 0.050 |
Why?
|
| Reference Values | 1 | 2012 | 93 | 0.050 |
Why?
|
| Vaccines, Conjugate | 1 | 2022 | 66 | 0.050 |
Why?
|
| Sex Distribution | 1 | 2012 | 198 | 0.050 |
Why?
|
| Recurrence | 1 | 2012 | 187 | 0.050 |
Why?
|
| Hospital Mortality | 1 | 2023 | 150 | 0.050 |
Why?
|
| Antiviral Agents | 1 | 2022 | 95 | 0.050 |
Why?
|
| Death, Sudden, Cardiac | 1 | 2011 | 36 | 0.050 |
Why?
|
| Mental Disorders | 2 | 2015 | 295 | 0.050 |
Why?
|
| Patient Safety | 1 | 2022 | 41 | 0.050 |
Why?
|
| Anxiety Disorders | 1 | 2022 | 93 | 0.050 |
Why?
|
| Anxiety | 1 | 2022 | 156 | 0.050 |
Why?
|
| Hypoglycemic Agents | 1 | 2013 | 288 | 0.050 |
Why?
|
| Stress, Psychological | 1 | 2022 | 147 | 0.050 |
Why?
|
| Deltoid Muscle | 1 | 2020 | 4 | 0.050 |
Why?
|
| Injections, Intramuscular | 1 | 2020 | 11 | 0.050 |
Why?
|
| Antibodies, Viral | 1 | 2020 | 65 | 0.050 |
Why?
|
| Disease Susceptibility | 1 | 2020 | 46 | 0.040 |
Why?
|
| Public Health Surveillance | 1 | 2020 | 45 | 0.040 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2009 | 18 | 0.040 |
Why?
|
| Health Status Disparities | 1 | 2021 | 153 | 0.040 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2009 | 73 | 0.040 |
Why?
|
| Myocardial Infarction | 1 | 2011 | 249 | 0.040 |
Why?
|
| Predictive Value of Tests | 1 | 2010 | 365 | 0.040 |
Why?
|
| Continental Population Groups | 1 | 2021 | 315 | 0.040 |
Why?
|
| Stroke | 1 | 2011 | 311 | 0.040 |
Why?
|
| Biomarkers | 1 | 2019 | 308 | 0.040 |
Why?
|
| Cross-Sectional Studies | 1 | 2022 | 1360 | 0.040 |
Why?
|
| Ethnic Groups | 1 | 2021 | 501 | 0.040 |
Why?
|
| Depression | 1 | 2022 | 518 | 0.040 |
Why?
|
| Asian Continental Ancestry Group | 1 | 2007 | 90 | 0.040 |
Why?
|
| Age Factors | 1 | 2020 | 965 | 0.040 |
Why?
|
| African Continental Ancestry Group | 1 | 2007 | 166 | 0.030 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2006 | 27 | 0.030 |
Why?
|
| Receptors, Estrogen | 1 | 2006 | 58 | 0.030 |
Why?
|
| Electronic Health Records | 1 | 2011 | 747 | 0.030 |
Why?
|
| Treatment Outcome | 1 | 2009 | 1296 | 0.030 |
Why?
|
| Bone Density | 1 | 2006 | 96 | 0.030 |
Why?
|
| Neoplasm Staging | 1 | 2006 | 337 | 0.030 |
Why?
|
| Databases, Genetic | 1 | 2013 | 10 | 0.030 |
Why?
|
| Models, Genetic | 1 | 2013 | 24 | 0.030 |
Why?
|
| Mother-Child Relations | 1 | 2013 | 14 | 0.030 |
Why?
|
| Health Maintenance Organizations | 1 | 2006 | 479 | 0.030 |
Why?
|
| Registries | 1 | 2006 | 490 | 0.030 |
Why?
|
| Genotype | 1 | 2013 | 253 | 0.030 |
Why?
|
| Phenotype | 1 | 2013 | 148 | 0.030 |
Why?
|
| Body Mass Index | 1 | 2007 | 974 | 0.030 |
Why?
|
| Sex Factors | 1 | 2015 | 661 | 0.030 |
Why?
|
| Health Status | 1 | 2015 | 328 | 0.030 |
Why?
|
| Chronic Disease | 1 | 2015 | 468 | 0.030 |
Why?
|
| Orbital Neoplasms | 1 | 1970 | 1 | 0.010 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 1970 | 25 | 0.010 |
Why?
|
| Cobalt Isotopes | 1 | 1970 | 1 | 0.000 |
Why?
|
| Eye Manifestations | 1 | 1970 | 1 | 0.000 |
Why?
|
| Eye Diseases | 1 | 1970 | 6 | 0.000 |
Why?
|